DSMM Track: Duke Scholars in Oncology and Cellular Therapies

Cancer remains one of the most harmful diseases worldwide and is the second leading cause of death in the United States. The American Cancer Society estimates that 1.6 million new cases of cancer are diagnosed each year and over 35% will result in death. The practice of oncology continually faces the challenge of matching the right therapeutic regimen with the right patient. This challenge is often daunting with only marginal success rates. As a result, new understanding of the biology of cancer is essential to developing better therapeutics and the ability to translate basic science discoveries into the clinical setting.

The Mission of the Duke Scholars in Oncology and Cellular Therapies (DSOC) Program is to provide training for pre-doctoral and post-doctoral scientists interested in cancer research and to promote opportunities for scientists to interact with physicians to gain experience and an understanding of the clinical problems in oncology.


What are the key program components?

The DSMM Oncology and Cellular Therapies track features several key components to facilitate a greater understanding and appreciation for translational medicine and clinical questions.

  • Direct interaction with clinicians and clinical scientists during patient care encounters across a wide range of adult and pediatric oncology subspecialties. Leading Duke Cancer Institute oncologists recognized for their teaching proficiency and mentoring were selected to form monthly rotations in the DCI in medical oncology and radiation oncology. 
  • Attend a national oncology meeting (American Society of Clinical Oncology (ASCO) or American Society of Hematology (ASH)) to network with national oncology experts and colleagues.
  • Attend specialty tumor boards and clinical conferences across the DCI and at a national level.
  • End of year presentation at Hematology-Oncology Grand Rounds to foster collaboration between scholars and members of the Duke Cancer Institute.

Who should apply?

Candidates should be in a pre-doctoral program or currently in a post-doctoral position and have an interest in cancer biology.

For more Information, contact:

Andrew Armstrong
David Hsu 
Stephanie Sarantopoulos

Oncology and Cellular Therapies Faculty

George Barth Geller Distinguished Professor for Research in Cancer
Professor of Medicine
Chief of Hematologic Malignancies and Cellular Therapy